Novo Nordisk share in historic slump – Weight loss trial disappoints

Novo Nordisk shares took a big hit after the Danish pharmaceutical company published new results from trials with the weight loss drug Cagrisema.

Novo Nordisk shares took a big hit Friday (photo: Novo Nordisk)

The trial participants achieved an average of 22.7 percent weight loss over a period of 68 weeks, Novo writes in a company announcement.This is less than what investors hoped and expected. The share fell by 27 percent for a period, but the loss is down to 15 percent past noon.The stock market had expected a […]


Gain unlimited access to all of The Copenhagen Post

Our independent reporting can only be published with support from our readers.

Monthly subscription

119

DKK/month.

(Billed once a month)

Give us a try

6 month subscription

99

DKK/month.

(Billed twice a year)

Save 120 DKK

Yearly subscription

79

DKK/month.

(Billed once a year)

Save 480 DKK

Save with a company subscription?